Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]
Videos
The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]
The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]
The expert panel comments on ideal patient profiles for SMA treatment with nusinersen, onasemnogene abeparvovec, and risdiplam. O painel de especialistas comenta os perfis ideais de pacientes para tratamento da atrofia muscular espinhal com nusinersena, onasemnogeno abeparvoveque e risdiplam.
Drs Rodrigo de Holanda Mendonça and Adriana Banzzatto Ortega discuss clinical trial data with nusinersen, onasemnogene abeparvovec, and risdiplam. Drs Rodrigo de Holanda Mendonça e Adriana Banzzatto Ortega discutem dados de testes clínicos com nusinersena, onasemnogeno abeparvoveque e risdiplam.
Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.
Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.
The pediatric neurologist at Nationwide Children's Hospital talked about current gaps and potential treatment approvals in epilepsy care for 2023. [WATCH TIME: 4 minutes]
The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]
The psychologist and professor in the department of rehabilitation medicine at the University of Washington shared her perspective on the state of mental health care in multiple sclerosis. [WATCH TIME: 4 minutes]
The pediatric neurologist at Nationwide Children's Hospital talked about the year-over-year changes in day-to-day clinical practice of patients with epilepsy. [WATCH TIME: 4 minutes]
The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]
The director of the Headache Center at Allegheny Health Network provided an overview of clinically relevant approaches to treat migraine at its core pathology. [WATCH TIME: 2 minutes]
The pediatric neurologist at Nationwide Children's Hospital spoke on several innovations and potential concerns in neurology clinicians should expect in 2023. [WATCH TIME: 6 minutes]
The executive director of Cure CMD discussed efforts being done to bring the stakeholder community together and improve the care for patients with congenital muscular dystrophies. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]
The psychologist and professor in the department of rehabilitation medicine at the University of Washington talked about the benefits of a new initiative from the National MS Society focusing on mental health. [WATCH TIME: 4 minutes]
The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed ways to build off the ARISE study and the unanswered questions regarding radiologically isolated syndrome. [WATCH TIME: 3 minutes]
The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]
Drs McDade, Atri, Cohen, and Sabbagh discuss candidates drugs and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease.
Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.
The vice dean for data science at Duke University School of Medicine spoke about the major disparities observed in models that assess stroke risk. [WATCH TIME: 4 minutes]
Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça provide an overview of available treatments for spinal muscular atrophy in Brazil. / Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discutem tratamentos para atrofia muscular espinhal disponíveis no Brasil.
Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discuss genetic changes in spinal muscular atrophy and genetic screening in Brazil. / Drs Juliana Gurgel Giannetti and Rodrigo de Holanda Mendonça discutem mudanças genéticas em atrofia muscular espinhal e screening genético no Brasil.
Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega and Marcelo Kerstenetzky discuss symptoms of spinal muscular atrophy and diagnosis and referral process in Brazil. / Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega e Marcelo Kerstenetzky discutem sintomas da atrofia muscular espinhal, diagnóstico e processo de encaminhamento no Brasil.
Dr Rodrigo de Holanda Mendonça provides an overview of spinal muscular atrophy (SMA). / Dr Rodrigo de Holanda Mendonça dá uma visão geral sobre Atrofia Muscular Espinhal (AME).
Ahead of the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas, the vice president of public policy and advocacy at the Muscular Dystrophy Association provided an overview of the current state of access and the need for more advocates in neuromuscular disease. [WATCH TIME: 14 minutes]
The vice dean for data science at Duke University School of Medicine talked about the main findings from his latest published study on stroke risk algorithms. [WATCH TIME: 3 minutes]
At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University talked about how clinicians and patients might define a seizure. [WATCH TIME: 3 minutes]
The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed the presentation of radiologically isolated syndrome and identifying candidates for treatment. [WATCH TIME: 4 minutes]
Advertisement
Advertisement
